Controlled trial with a monthly combination injectable contraceptive in the USA

A monthly injectable contraceptive combining estradiol cypionate and medrox yprogesterone acetate was found to be well tolerated and effective in a pha se III prospective, multicenter trial conducted in the United States. In th is open-label comparison with an oral contraceptive, there were no pregnanc ies in the group receiving the monthly combination injectable contraceptive versus one pregnancy in those receiving the oral contraceptive. The rates of discontinuation for adverse events in the two treatment groups over the 60-week trial did not differ significantly. The majority of patients in bot h groups reported satisfaction with the method of contraception which they were receiving.